Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901149 | 0.90 | MAPT (0.49) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901150 | 0.89 | MAPK1 (0.42) | BRAFMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL14901144 | 0.84 | FGFR1 (0.43) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901213 | 0.83 | PIK3CA (0.53) | ATRNPC1RAB9AABCB1BRAF | |
| SCHEMBL14901120 | 0.82 | FGFR3 (0.54) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901156 | 0.80 | FGFR3 (0.47) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901249 | 0.77 | FGFR3 (0.42) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901399 | 0.77 | FGFR1 (0.51) | KDR | |
| SCHEMBL14901254 | 0.77 | FGFR1 (0.49) | KDR | |
| SCHEMBL14901155 | 0.77 | TTK (0.42) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | ATR 3622/4885NPC1 763/4885RAB9A 2422/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | ATR 574/4885NPC1 3720/4885RAB9A 3687/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ATR 691/4885NPC1 4321/4885RAB9A 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.